Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily

Author： Porst Hartmut   Hell-Momeni Katja   Büttner Hartwig  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.10, 2012-07, pp. : 1481-1494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction

By Kuan James   Brock Gerald  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1605-1613

Informa Healthcare

Access to resources Recommend Favorite

Review of tadalafil in the treatment of erectile dysfunction

By Meuleman Eric JH  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 11, 2003-11 ,pp. : 2049-2056

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Novel PDE5 inhibitors for the treatment of male erectile dysfunction

By Kalsi JS   Bahadur G   Muneer A   Ozturk O   Christopher N   Ralph DJ   Minhas S  

Reproductive BioMedicine Online, Vol. 7, Iss. 4, 2003-10 ,pp. : 456-461

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Tadalafil population pharmacokinetics in patients with erectile dysfunction

By Trocóniz Iñaki   Tillmann Christiane   Staab Alexander   Rapado Javier   Forgue S.  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 6, 2007-06 ,pp. : 583-590

Springer Publishing Company

Access to resources Recommend Favorite